0KSX Stock Chart & Stats
$230.38
$5.88(2.55%)
At close: 4:00 PM EDT
$230.38
$5.88(2.55%)
Day’s Range― - ―
52-Week Range$171.60 - $256.06
Previous CloseN/A
Volume36.00
Average Volume (3M)171.00
Market Cap
$25.68B
Enterprise Value$29.88B
Total Cash (Recent Filing)$626.00M
Total Debt (Recent Filing)$6.38B
Price to Earnings (P/E)24.4
Beta0.44
Next Earnings
Oct 22, 2026EPS Estimate
2.87Next Dividend Ex-DateN/A
Dividend Yield1.45%
Share Statistics
EPS (TTM)9.54
Shares Outstanding110,373,360
10 Day Avg. Volume102
30 Day Avg. Volume171
Financial Highlights & Ratios
PEG Ratio1.43
Price to Book (P/B)2.69
Price to Sales (P/S)1.75
P/FCF Ratio14.17
Enterprise Value/Market Cap1.16
Enterprise Value/Revenue2.58
Enterprise Value/Gross Profit7.80
Enterprise Value/Ebitda13.42
Forecast
1Y Price Target
$256.00Price Target Upside11.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)11.2
Revenue Forecast (FY)$12.01B
Bulls Say, Bears Say
Bulls Say
Strong Volume And Revenue GrowthDouble-digit requisition and revenue growth indicates broadening demand for Quest’s diagnostic services, supported by both organic expansion and major health-system relationships. Sustained volume growth can improve network utilization, deepen customer relationships, and provide a durable foundation for earnings growth.
Advanced Diagnostics ExpansionHaystack MRD’s reported clinical performance and broad tumor-type validation strengthen Quest’s position in specialized oncology diagnostics. Greater adoption of high-complexity testing can expand the company’s clinical relevance, support differentiated offerings, and improve its long-term mix toward advanced services.
Automation And Productivity InitiativesAutomation and AI investments can create lasting operating advantages by improving laboratory productivity, specimen collection efficiency, and supply management. Progress toward the Invigorate cost-savings target supports margin resilience and gives Quest additional capacity to reinvest in growth and technology.
Bears Say
Medicare Reimbursement PressureThe proposed CMS rate alignment creates a multi-year reimbursement headwind for laboratory services, with final rates still pending and reductions scheduled to phase in through 2029. Lower government payment rates could pressure revenue per test and require continued productivity gains to protect profitability.
Margin Pressure From Mix And Investment CostsThe margin decline shows that growth is not converting fully into operating leverage as Project Nova spending, health-system relationship mix, and compensation costs weigh on profitability. If these pressures persist, normalized margins may remain below prior peaks despite continued revenue expansion.
Moderate Leverage Limits FlexibilityDebt remains sizable relative to shareholder equity, which reduces financial flexibility if operating conditions weaken or reimbursement pressure intensifies. Interest and refinancing obligations can constrain capital allocation, leaving less capacity for acquisitions, technology investment, or shareholder returns.
Quest Diagnostics News
0KSX FAQ
What was Quest Diagnostics’s price range in the past 12 months?
Quest Diagnostics lowest share price was $171.60 and its highest was $256.06 in the past 12 months.
What is Quest Diagnostics’s market cap?
Quest Diagnostics’s market cap is $25.68B.
When is Quest Diagnostics’s upcoming earnings report date?
Quest Diagnostics’s upcoming earnings report date is Oct 22, 2026 which is in 9 days.
How were Quest Diagnostics’s earnings last quarter?
Quest Diagnostics released its earnings results on Jul 23, 2026. The company reported $3.12 earnings per share for the quarter, beating the consensus estimate of $2.823 by $0.297.
Is Quest Diagnostics overvalued?
According to Wall Street analysts Quest Diagnostics’s price is currently Undervalued.
Does Quest Diagnostics pay dividends?
Quest Diagnostics pays a Quarterly dividend of $0.86 which represents an annual dividend yield of 1.45%. See more information on Quest Diagnostics dividends here
What is Quest Diagnostics’s EPS estimate?
Quest Diagnostics’s EPS estimate is 2.87.
How many shares outstanding does Quest Diagnostics have?
Quest Diagnostics has 110,373,360 shares outstanding.
What happened to Quest Diagnostics’s price movement after its last earnings report?
Quest Diagnostics reported an EPS of $3.12 in its last earnings report, beating expectations of $2.823. Following the earnings report the stock price went up 6.921%.
Which hedge fund is a major shareholder of Quest Diagnostics?
Currently, no hedge funds are holding shares in GB:0KSX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Quest Diagnostics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$256.00 (11.12% Upside)
$256.00 (11.12% Upside)
Blogger Sentiment
Bullish
GB:0KSX Sentiment 70%
Sector Average 66%
Sector Average 66%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.50%
12-Months-Change
Fundamentals
Return on Equity
14.49%
Trailing 12-Months
Asset Growth
6.07%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Quest Diagnostics
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
0KSX Company Deck
0KSX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong operational and commercial momentum: double-digit revenue growth, robust volume expansion, notable diagnostic and commercial milestones (Haystack MRD approval, Flatiron integration), meaningful adjusted EPS growth (+19.1%) and a raised full-year guide. Offsetting these positives are short-term margin pressures (70 bps headwind in Q2 from Nova ramp, Corewell/Fresenius mix and deferred compensation), higher expected H2 costs (fuel and Nova), and regulatory reimbursement risk (PAMA uncertainty and a ~30 bps ACA headwind). On balance, the positives (top-line strength, EPS improvement, raised guidance, product/partnership milestones, and productivity/automation investments) significantly outweigh the headwinds.View all GB:0KSX earnings summaries0KSX Revenue Breakdown
97.73% Diagnostic Information Services
2.27% DS businesses
0KSX Stock 12 Month Forecast
Average Price Target
$256.00
▲(11.12% Upside)